Since 1998, there have been multiple separate outbreaks of Bluetongue disease (BT) in
Europe with the largest outbreak ever recorded in Northern Europe caused by Bluetongue …

Background A candidate recombinant, live-attenuated, CYD tetravalent dengue vaccine
(CYD-TDV) has recently demonstrated immunogenicity, efficacy and good tolerability. This …

Bluetongue virus (BTV) and African horse sickness virus (AHSV) are widespread
arboviruses that cause important economic losses in the livestock and equine industries …

There is currently no licensed vaccine for noroviruses, and development is hindered, in part,
by an incomplete understanding of the host adaptive immune response to these highly …

To the Editor: Dengue is one of the most widespread infectious diseases globally;
transmission now occurs in 128 countries. Although dengue virus (DENV) control strategies …

Dengue virus is a significant public health threat worldwide; however, the pathogenesis of
dengue disease remains poorly understood due to lack of appropriate small animal models …

Background We assessed replication and excretion of the live attenuated tetravalent dengue
vaccine (CYD-TDV) into biological fluids following vaccination in dengue-naive adults in …

Background. Live, multivalent vaccines have historically exhibited interference in humans;
live dengue virus (DENV) vaccines have proven no exception. Methods. To characterize …

Background Dengue (DEN) viruses have become a public health problem that affects
approximately 100 million people worldwide each year. Prevention measures rely on vector …

Our group developed a subunit vaccine candidate against dengue virus based on two
different viral regions: the domain III of the envelope protein and the capsid protein. The …